Buyout
We invest our own capital in the lower and upper midcap segments to support the transformation efforts of highpotential companies and accelerate their international expansion. We work alongside management teams, helping our investees
to strengthen and scale up in three main ways: through international expansion, digital transformation and acquisitions.
We invest on behalf of Eurazeo and our partner investors, in companies that have solid fundamentals, established positions in promising markets, real growth potential and ambitious management teams.
We favor the life sciences, tech, financial services and consumer goods sectors, in which we have proven, well-known expertise. Our team identifies the best investment opportunities in those sectors and provides unrivaled strategic and operational support to our portfolio companies.
We work alongside managers, helping our investees to strengthen and grow in three main ways: through international expansion, digital transformation and acquisitions.
We bring them the financial, strategic and human resources they need. This includes an effective on-the-ground presence in four continents – giving them easier access to new markets, particularly in China – along with a dedicated team of digital experts skilled in optimizing operational performance. Our buyout teams are also backed up by Eurazeo’s corporate departments and an international network of more than 120 high-level experts.
-
50
expertsin Europe
-
€10
billionof Assets Under Management (AuM) as of 31/12/2024
-
29
portfoliocompanies
Team Leaders
Capital
Eurazeo’s Capital strategy targets the upper midcap segment, with the ambition to support high-potential companies that are already market leaders or on the path to becoming so. As a long-term investor, we bring to them our sector expertise, our ability to structure complex transactions, and our strong European and global footprint to accelerate their transformation, international expansion, and sustainable growth.
Our ability to deploy substantial resources from the outset, deep operational commitment and align strongly with management teams is a key differentiator in supporting ambitious and sustainable growth trajectories.
The Capital team focuses on typical equity tickets beyond 200m€ in three high-growth sectors where Eurazeo has deep expertise: technology-enabled business services, life sciences and healthcare, and financial services. These sectors are at the heart of major economic and societal transitions and offer long-term opportunities for sustainable value creation.
We are the partner of choice for managers who want to grow their businesses. We provide them with leading-edge expertise, a team of committed experts, a global network and financial resources to match their ambitions.
Investments
Elevate
Eurazeo’s Elevate strategy targets the Lower Mid Cap segment, with the ambition to support high-quality European companies experiencing strong growth and often facing a strategic turning point in their development. Working alongside ambitious entrepreneurs, we leverage our expertise to accelerate their growth, particularly through buy-and-build strategies, the structuring of more robust organizations, and the implementation of key levers to help build the European and global leaders of tomorrow.
Our approach is based on active engagement, with equity tickets typically up to €150 million, and a strong ability to support companies over the long term as they scale and evolve strategically. This flexibility, combined with operational support, is a key asset in helping businesses cross critical growth thresholds.
The Elevate team focuses its investments primarily on the technology and business services sectors, which are key drivers of innovation and transformation in the European and global economy. These sectors offer strong potential for long-term sustainable value creation, in line with today’s major economic and societal transitions.
We help French SMEs expand internationally, to turn them into mid-cap companies. We maintain daily contact with them, helping them to set up the necessary structures, introduce new processes and raise non-financial challenges.
China: a fund to accelerate startups’ development
The Eurazeo China Acceleration Fund’s mission is to invest alongside Eurazeo in French and European companies operating in sectors with strong growth potential in the Chinese market, and to support them with their strategies. Eurazeo is responsible for managing the fund, including selecting and managing investments. Since it was created the fund – set up in partnership with sovereign fund China Investment Corporation and BNP Paribas – has invested in 9 companies: DORC, UTAC, Questel, Planet, Neoxam, BMS, Efeso, Scaled Agile and Rydoo.
Latest news
10/07/2025 - PRESS RELEASES
Eurazeo enters into exclusive discussions regarding the sale of its stake in the CPK Group
min
04/03/2025 - PRESS RELEASES
Eurazeo announces final closing of its "Eurazeo Capital V" fund
min
11/12/2024 - PRESS RELEASES
Eurazeo enters into exclusive discussions regarding the sale of its stake in Albingia
min
22/11/2024 - PRESS RELEASES
Eurazeo raises a €180 million continuation fund to support I-TRACING
min
18/06/2024 - PRESS RELEASES
Eurazeo invests in Rydoo, the fast-growing international expense management software provider
min
10/06/2024 - PRESS RELEASES
Eurazeo and the management of I-Tracing enter into exclusive discussions with a view to welcoming Oakley as a reference shareholder
min
22/04/2024 - PRESS RELEASES
Eurazeo to invest in Eres Group, the leading French independent player in profit-sharing solutions and retirement schemes
1 min
03/04/2024 - PRESS RELEASES
Eurazeo completes the sale of DORC to Carl Zeiss Meditec AG
1 min
17/12/2023 - PRESS RELEASES
Eurazeo enters into exclusive discussions with Carl Zeiss Meditec AG to sell its stake in DORC
1 min
23/12/2022 - PRESS RELEASES
Eurazeo to invest in BMS group, a high growth independent (re)insurance broker, alongside BCI, PCP and management
1 min
19/07/2022 - PRESS RELEASES
Eurazeo raises over €1 billion for Eurazeo PME IV fund
1 min
12/07/2022 - PRESS RELEASES
Eurazeo enters into exclusive discussions with Apax Partners for the sale of its majority stake in Vitaprotech
1 min
07/07/2022 - PRESS RELEASES
Eurazeo completes the sale of its stake in Orolia Group
1 min
29/06/2022 - PRESS RELEASES
Eurazeo to sell the remaining 51% of its stake in Trader Interactive
1 min
15/06/2022 - PRESS RELEASES
Eurazeo signs an agreement to invest more than €70 million in WiiSmile
1 min
26/01/2022 - PRESS RELEASES
Eurazeo invests in cranial technologies, the market leader in treating infant plagiocephaly
1 min
